drugset / Trial / NCT03682796
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
Timeline
- Start
- 2018-10-15
- Primary completion
- 2021-11-17
- Completion
- 2021-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRPH-222 | Other / unclassified | — | Intravenous |